Finally published underlining the safety of COVID-19 vaccination under immune checkpoint therapy, focusing on a specific adverse event: cytokine release syndrome.
doi.org/10.1038/s43018-022-0…
Great experience working cofirst @SunanjayB and Guy Ungerechts. (1/6)
Aquesta setmana, a l'IDIBAPS...
Thomas Walle s'incorpora a l'#IDIBAPS com a cap del grup "Biomedicina computacional del cĂ ncer"
La seva recerca s'ha centrat en el rol de les cèl·luels immunità ries en l'èxit del tractament contra el cà ncer
👉f.mtr.cool/tbdratetpo
Excited to share a major level-up in my transition to IDIBAPS — and we’re hiring!
We are particularly looking for international PhD candidates to join the DYNAMIS program — with only 2 weeks left to apply.
apply here:
lnkd.in/dTjRxs3Z
1/7
RL20 — Cholangiocarcinoma: Map early systemic immune reprogramming with single-cell multiomics to improve early detection and identify new immunotherapies therapy. with Teresa Macarulla
6/7
This builds on models pioneered by Niels Halama and preserves real tumor architecture and cell–cell interactions, letting us study SASP in a setting far closer to the patient’s tumor than cell culture.
8/9
6/ What does this mean?
Radiotherapy-immune crosstalk is robust but limited
Immune modulation will require targeting sets of chemokines
Dose escalation alone can’t push beyond the biological ceiling
Understanding these concepts is key to better radio-immunotherapies
9/9